Eradicating HIV-1 infection: Seeking to clear a persistent pathogen

Nature Reviews Microbiology

Volumn 12, Issue 11, 2014, Pages 750-764

  Archin, Nancie M ^a   Sung, Julia Marsh ^a   Garrido, Carolina ^a   Soriano Sarabia, Natalia ^a   Margolis, David M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CELL DNA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4+ T LYMPHOCYTE; CLEARANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; INFECTION; INFECTION CONTROL; LATENT PERIOD; MACROPHAGE; MEMORY T LYMPHOCYTE; NONHUMAN; PATHOGEN CLEARANCE; PERSISTENT INFECTION; PRIORITY JOURNAL; RESERVOIR; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS GENOME; ANIMAL; CELL LINE; DISEASE ERADICATION; DISEASE MODEL; HIV INFECTIONS; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DISEASE ERADICATION; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; VIREMIA; VIRUS INTEGRATION; VIRUS LATENCY;

EID: 84922481194     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3352     Document Type: Review

References (187)

1. Persaud, D. in 20th International AIDS Conference. Symposium presentation MOSY0501 (International AIDS Society, 2014).
2. Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319-327 (2014).
3. Chun, T. W. et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Med. 1, 1284-1290 (1995).
4. + T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869-8873 (1998).
5. Strain, M. C. et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191, 1410-1418 (2005).
6. + cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl Acad. Sci. USA 109, 9523-9528 (2012).
7. + T cells in the absence of activating stimuli. J. Virol. 79, 14179-14188 (2005).
8. Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423-427 (1991).
9. Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
10. + T cells. J. Virol. 79, 2199-2210 (2005).
11. + T cells. Nature Med. 9, 727-728 (2003).
12. Calvanese, V., Chavez, L., Laurent, T., Ding, S. & Verdin, E. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 446, 283-292 (2013).
13. + T lymphocytes in vivo. J. Virol. 77, 7383-7392 (2003).
14. + T cells in virally suppressed subjects. J. Virol. 87, 9148-9158 (2013).
15. Josefsson, L. et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl Acad. Sci. USA 110, 25 (2013).
16. Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog. 10, e1004010 (2014).
17. Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105, 3879-3884 (2008).
18. Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627-1632 (1999).
19. Grossman, Z. et al. Ongoing HIV dissemination during HAART. Nature Med. 5, 1099-1104 (1999).
20. Frenkel, L. M. et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J. Virol. 77, 5721-5730 (2003).
21. Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Med. 16, 460-465 (2010).
22. Sigal, A. et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98 (2011).
23. Permanyer, M. et al. Antiretroviral agents effectively block HIV replication after cell-to-cell transfer. J. Virol. 86, 8773-8780 (2012).
24. Agosto, L. M., Zhong, P., Munro, J. & Mothes, W. Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. PLoS Pathog. 10, e1003982 (2014).
25. Titanji, B. K., Aasa-Chapman, M., Pillay, D. & Jolly, C. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology 10, 1742-4690 (2013).
26. Yukl, S. A. et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 24, 2451-2460 (2010).
27. Vallejo, A. et al. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 26, 1885-1894 (2012).
28. Gandhi, R. T. et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Def. Syndr. 59, 229-235 (2012).
29. Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307-2312 (2014).
30. Anton, P. A. et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses 28, 1412-1421 (2012).
31. Robbins, B. L., Nelson, S. R. & Fletcher, C. V. A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts. J. Pharm. Biomed. Anal. 70, 378-387 (2012).
32. Kieffer, T. L. et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189, 1452-1465 (2004).
33. + T cells. J. Virol. 80, 6441-6457 (2006).
34. Evering, T. H. et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 8, e1002506 (2012).
35. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Med. 15, 893-900 (2009).
36. + T cells. PLoS Pathog. 7, 6 (2011).
37. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179-183 (2014).
38. Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570-573 (2014).
39. Margolis, D. & Bushman, F. HIV/AIDS. Persistence by proliferation? Science 345, 143-144 (2014).
40. Lewinski, M. K. et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79, 6610-6619 (2005).
41. Shan, L. et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 85, 5384-5393 (2011).
42. Sherrill-Mix, S. et al. HIV latency and integration site placement in five cell-based models. Retrovirology 10, 1742-4690 (2013).
43. Verdin, E., Paras, P. Jr & Van Lint, C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12, 3249-3259 (1993).
44. Keedy, K. S. et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83, 4749-4756 (2009).
45. Friedman, J. et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85, 9078-9089 (2011).
46. Mbonye, U. & Karn, J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454-455, 328-339 (2014).
47. du Chene, I. et al. Suv39H1 and HP1γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424-435 (2007).
48. Herrmann, C. H. & Rice, A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69, 1612-1620 (1995).
49. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Ta t and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451-462 (1998).
50. + T cells. J. Virol. 87, 1211-1220 (2013).
51. Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. Retrovirology 10, 1742-4690 (2013).
52. Descours, B. et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin. Infect. Dis. 54, 1495-1503 (2012).
53. + cell subsets within one month post-infection. PLoS ONE 8, e64219 (2013).
54. Soriano-Sarabia, N., Archin, N. & Margolis, D. in Conference on Retroviruses and Opportunistic Infections. Abstract 46 (2013).
55. Zhang, J. & Crumpacker, C. S. Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution. Cell Res. 20, 745-747 (2010).
56. Carter, C. C. et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe 9, 223-234 (2011).
57. Carter, C. C. et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med. 16, 446-451 (2010).
58. + hematopoietic progenitor cells in most patients on antiretroviral therapy. J. Infect. Dis. 205, 1014-1018 (2012).
59. Josefsson, L. et al. Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J. Infect. Dis. 206, 28-34 (2012).
60. + T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J. Infect. Dis. 202, 1738-1748 (2010).
61. + T cells with stem cell-like properties. Nature Med. 20, 139-142 (2014).
62. Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573-584 (2013).
63. Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nature Med. 17, 1290-1297 (2011).
64. + cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate. J. Immunol. 189, 5212-5222 (2012).
65. Morita, C. T. et al. Structural features of nonpeptide prenyl pyrophosphates that determine their antigenicity for human γδ T cells. J. Immunol. 167, 36-41 (2001).
66. Hintz, M. et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett. 509, 317-322 (2001).
67. Poupot, M. & Fournie, J. J. Non-peptide antigens activating human Vγ9/Vδ2 T lymphocytes. Immunol. Lett. 95, 129-138 (2004).
68. Vavassori, S. et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nature Immunol. 14, 908-916 (2013).
69. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl Acad. Sci. USA 98, 658-663 (2001).
70. Gartner, S. et al. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219 (1986).
71. Koenig, S. et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 1089-1093 (1986).
72. Lambotte, O. et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J. Acquir. Immune Def. Syndr. 23, 114-119 (2000).
73. Price, R. W. et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239, 586-592 (1988).
74. Gorry, P. R. et al. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Ta t and Rev. J. Virol. 73, 352-361 (1999).
75. Sieweke, M. H. & Allen, J. E. Beyond stem cells: self-renewal of differentiated macrophages. Science 342, 1242974 (2013).
76. Queen, S. E. et al. Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J. Virol. 85, 9167-9175 (2011).
77. Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630-634 (2012).
78. Garcia-Martinez, J. in HIV Persistence During Therapy, Sixth International Workshop. Abstract 17 (IHL Press, 2013).
79. Margolis, D. M. How might we cure HIV? Curr. Infect. Dis. Rep. 16, 392 (2014).
80. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
81. Yang, H. C. et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119, 3473-3486 (2009).
82. + T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc. Natl Acad. Sci. USA 107, 16934-16939 (2010).
83. + T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110, 4161-4164 (2007).
84. Lassen, K. G., Hebbeler, A. M., Bhattacharyya, D., Lobritz, M. A. & Greene, W. C. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS ONE 7, e30176 (2012).
85. Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 1868-1877 (2003).
86. + T cells. Blood 113, 58-65 (2009).
87. Bosque, A. & Planelles, V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53, 54-61 (2011).
88. + cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84, 6425-6437 (2010).
89. + T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013).
90. Hakre, S., Chavez, L., Shirakawa, K. & Verdin, E. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36, 706-716 (2012).
91. Barton, K. M., Burch, B. D., Soriano-Sarabia, N. & Margolis, D. M. Prospects for treatment of latent HIV. Clin. Pharmacol. Ther. 93, 46-56 (2013).
92. Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118-130 (2007).
93. + cell transplantation. Blood 108, 487-492 (2006).
94. Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nature Med. 12, 1316-1322 (2006).
95. Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).
96. Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83, 7305-7321 (2009).
97. Denton, P. W. et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5, e8829 (2010).
98. Marsden, M. D. et al. HIV latency in the humanized BLT mouse. J. Virol. 86, 339-347 (2012).
99. Long, B. R. & Stoddart, C. A. aainterferon and HIV infection cause activation of human T cells in NSG-BLT mice. J. Virol. 86, 3327-3336 (2012).
100. + thymocytes. Retrovirology 9, 44 (2012).
101. + T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204, 705-714 (2007).
102. Denton, P. W. et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014).
103. Vatakis, D. N. et al. Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J. Vis. Exp. 70, e4181 (2012).
104. Shimizu, S. et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115, 1534-1544 (2010).
105. Honeycutt, J. B. et al. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 10, 121 (2013).
106. Dinoso, J. B. et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83, 9247-9257 (2009).
107. Clements, J. E., Gama, L., Graham, D. R., Mankowski, J. L. & Zink, M. C. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr. Opin. HIV AIDS 6, 37-42 (2011).
108. Hirsch, V. M., Zack, P. M., Vogel, A. P. & Johnson, P. R. Simian immunodeficiency virus infection of macaques: end-stage disease is characterized by widespread distribution of proviral DNA in tissues. J. Infect. Dis. 163, 976-988 (1991).
109. Horiike, M. et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 423, 107-118 (2012).
110. Baskin, G. B. et al. Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys. AIDS Res. Hum. Retroviruses 11, 273-285 (1995).
111. + T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77, 4938-4949 (2003).
112. Clements, J. E. et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J. Infect. Dis. 186, 905-913 (2002).
113. Clements, J. E. et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J. Neurovirol. 11, 180-189 (2005).
114. Zink, M. C. et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J. Infect. Dis. 202, 161-170 (2010).
115. Van Rompay, K. K. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 85, 159-175 (2010).
116. Deere, J. D. et al. Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART. PLoS ONE 9, e87914 (2014).
117. North, T. W. et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84, 2913-2922 (2010).
118. + lymphocytes. Science 283, 857-860 (1999).
119. + T cell epitope recognition paradigms. Science 340, 1237874 (2013).
120. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
121. Mavigner, M. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. Abstract 416 (2014).
122. Kiem, H. P. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. Abstract 419 (2014).
123. Spivak, A. M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883-890 (2014).
124. Prins, J. M. et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405-2410 (1999).
125. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
126. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782-6789 (2009).
127. Kauder, S. E., Bosque, A., Lindqvist, A., Planelles, V. & Verdin, E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5, e1000495 (2009).
128. Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5, e1000554 (2009).
129. Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D. & Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Med. 20, 425-429 (2014).
130. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
131. Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21, 277-285 (2013).
132. Rasmussen, T. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 438LB (2014).
133. Elliot, J. et al. in Highlights of the 20th conference on retroviruses and opportunistic infections. Top. Antivir. Med. 21 Abstract 50LB (2013).
134. Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 10, e1004071 (2014).
135. Archin, N. M. et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J. Infect. Dis. 210, 728-735 (2014).
136. Yang, K. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 435 (2014).
137. Graf, E. H. et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS ONE 8, e71879 (2013).
138. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
139. Burnett, J. C. et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84, 5958-5974 (2010).
140. Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4, 0006093 (2009).
141. Bernhard, W. et al. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett. 585, 3549-3554 (2011).
142. Fernandez, G. & Zeichner, S. L. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7, 266 (2010).
143. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).
144. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501 (2012).
145. Khaitan, A. & Unutmaz, D. Revisiting immune exhaustion during HIV infection. Curr. HIV/AIDS Rep. 8, 4-11 (2011).
146. Moir, S. et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205, 1797-1805 (2008).
147. Goulder, P. J. & Watkins, D. I. HIV and SIV CTL escape: implications for vaccine design. Nature Rev. Immunol. 4, 630-640 (2004).
148. Papuchon, J. et al. Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine. PLoS ONE 8, e69029 (2013).
149. Garcia, F., Leon, A., Gatell, J. M., Plana, M. & Gallart, T. Therapeutic vaccines against HIV infection. Hum. Vaccin. Immunother. 8, 569-581 (2012).
150. Gay, C. et al. in Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 344 (2014).
151. Casazza, J. P. et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 207, 1829-1840 (2013).
152. + individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117, 5391-5402 (2011).
153. Sung, J. et al. in Sixth International Workshop on HIV Persistence during Therapy Abstract 58 (IHL Press, 2013).
154. Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49 (2011).
155. Groscurth, P. Cytotoxic effector cells of the immune system. Anat. Embryol. 180, 109-119 (1989).
156. Hudspeth, K. et al. Engagement of NKp30 on Vδ1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood 119, 4013-4016 (2012).
157. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. & Zitvogel, L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nature Immunol. 9, 486-494 (2008).
158. Steel, J. C., Waldmann, T. A. & Morris, J. C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33, 35-41 (2012).
159. Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844-3855 (2013).
160. Bonsignori, M. et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11521-11532 (2012).
161. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
162. Varela-Rohena, A. et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nature Med. 14, 1390-1395 (2008).
163. Heslop, H. E. Genetic engineering of T-cell receptors: TCR takes to titin. Blood 122, 853-854 (2013).
164. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
165. Leng, Q., Bentwich, Z., Magen, E., Kalinkovich, A. & Borkow, G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 16, 519-529 (2002).
166. + T cell levels in humanized mice. J. Immunol. 190, 211-219 (2013).
167. Pincus, S. H. Therapeutic potential of anti-HIV immunotoxins. Antiviral Res. 33, 1-9 (1996).
168. Davey, R. T. Jr et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J. Infect. Dis. 170, 1180-1188 (1994).
169. Bera, T. K. et al. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 4, 384-391 (1998).
170. Dadachova, E. et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 3, e427 (2006).
171. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
172. Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
173. Hatano, H. et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 9, 10 (2013).
174. Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. J. Clin. Microbiol. 32, 732-739 (1994).
175. + T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 304, 3-15 (2005).
176. Archin, N. M. et al. Special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top. Antivir. Med. 22, e-1 Abstract 406 (2014).
177. Rouzioux, C. & Richman, D. How to best measure HIV reservoirs? Curr. Opin. HIV AIDS 8, 170-175 (2013).
178. Pasternak, A. O., Lukashov, V. V. & Berkhout, B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10, 1742-4690 (2013).
179. Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531-4536 (2003).
180. Strain, M. C. & Richman, D. D. New assays for monitoring residual HIV burden in effectively treated individuals. Curr. Opin. HIV AIDS 8, 106-110 (2013).
181. Strain, M. C. et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS ONE 8, e55943 (2013).
182. Kiselinova, M. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS ONE 9, e85999 (2014).
183. Sanchez, G., Xu, X., Chermann, J. C. & Hirsch, I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J. Virol. 71, 2233-2240 (1997).
184. + T cells in vivo. J. Virol. 79, 1975-1980 (2005).
185. Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).
186. + T cells. J. Virol. 85, 5220-5223 (2011).
187. + T cells. J. Virol. http://dx.doi.org/10.1128/JVI.01900-14 (2014).